CompletedPhase 2NCT02550873
A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Bernt van den Blink, MD, PhDHoffmann-La Roche
- Intervention
- PRM-151(biological)
- Enrollment
- 117 enrolled
- Eligibility
- 40-80 years · All sexes
- Timeline
- 2015 – 2017
Study locations (18)
- UCSF Interstitial Lung Disease Program, San Francisco, California, United States
- National Jewish Medical and Research Center, Denver, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Louisville Hospital, Louisville, Kentucky, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- UT - Southwestern Medical School, Dallas, Texas, United States
- Inova Fairfax Hospital, Falls Church, Virginia, United States
- University of Washington Medical Center, Seattle, Washington, United States
- University of Wisconsin-Madison, Madison, Wisconsin, United States
- Thomayer Hospital, Prague, Czechia
- Justus-Liebig University Giessen, Giessen, Germany
- Thoraxklinik University of Heidelberg, Heidelberg, Germany
- Az. Ospedaliera Universitaria-Policlinico V. Emanuele di Catania, Catania, Italy
- Azienda Ospedaliera San Gerardo, Monza, Italy
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02550873 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGPHASE2NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRein Therapeutics
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center